A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302. [EXTENSION OF 23608 & 29662]

Trial Profile

A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302. [EXTENSION OF 23608 & 29662]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2013

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Elan Pharmaceuticals; JANSSEN Alzheimer Immunotherapy
  • Most Recent Events

    • 09 Aug 2012 Checked against EudraCT
    • 06 Aug 2012 Status changed from recruiting to discontinued.
    • 20 Mar 2012 Additional trial location (Austria) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top